精神病性障碍患者脑脊液生物标志物与健康对照的系统综述与荟萃分析
该系统综述与荟萃分析纳入145项研究、覆盖197种脑脊液生物标志物,比较精神病性障碍患者与健康对照。发现去甲肾上腺素、IL-6、IL-8、犬尿喹啉酸等55种标志物与精神病性障碍相关,而多巴胺代谢产物无显著差异,提示免疫、肾上腺素能系统失调及血脑屏障功能障碍参与病理生理。
要点
- 精神病性障碍患者脑脊液去甲肾上腺素、IL-6、IL-8、犬尿喹啉酸等升高。
- 神经降压素和γ-氨基丁酸在患者脑脊液中降低。
- 多巴胺代谢产物高香草酸和DOPAC无显著差异。
核心结论
- 免疫和肾上腺素能系统失调以及血脑屏障功能障碍可能参与精神病性障碍的病理生理。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、EMBASE、Cochrane Library、Web of Science、ClinicalTrials.gov和PsycINFO截至2023年1月25日的研究。
- 纳入145项研究,覆盖197种脑脊液生物标志物,其中163种此前未在荟萃分析中研究过。
- 采用随机效应分析比较患者与健康对照,并进行发表偏倚评估、亚组和敏感性分析。
主要发现
- 55种脑脊液生物标志物与精神病性障碍相关,其中15种在≥2项研究中测量。
- 患者去甲肾上腺素(SMD 0.53;95%CI 0.16-0.90)及其代谢物MHPG(SMD 0.30;95%CI 0.05-0.55)升高。
- 患者5-羟吲哚乙酸(SMD 0.11;95%CI 0.01-0.21)、犬尿喹啉酸(SMD 1.58;95%CI 0.34-2.81)、犬尿氨酸(SMD 0.99;95%CI 0.60-1.38)升高。
- 患者IL-6(SMD 0.58;95%CI 0.39-0.77)、IL-8(SMD 0.43;95%CI 0.24-0.62)、anandamide(SMD 0.78;95%CI 0.53-1.02)升高。
- 患者白蛋白比(SMD 0.40;95%CI 0.08-0.72)、总蛋白(SMD 0.29;95%CI 0.16-0.43)、免疫球蛋白比(SMD 0.45;95%CI 0.06-0.85)、葡萄糖(SMD 0.48;95%CI 0.01-0.94)升高;神经降压素(SMD -0.67;95%CI -0.89至-0.46)和GABA(SMD -0.29;95%CI -0.50至-0.09)降低。
关键数值与推荐
- 所有纳入研究均显示一定程度偏倚。
- 多数生物标志物无显著差异,包括多巴胺代谢产物高香草酸和3,4-二羟基苯乙酸。
临床怎么用
- 脑脊液免疫和肾上腺素能标志物及血脑屏障功能指标可能为精神病性障碍提供病因线索和诊断工具。
- 目前证据尚不支持将脑脊液生物标志物常规用于临床诊断,需进一步验证。
局限性
- 所有纳入研究均存在一定程度偏倚。
- 多数生物标志物仅少数研究测量,部分标志物异质性高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychotic disorders are severe mental disorders with poorly understood etiology. Biomarkers in the cerebrospinal fluid (CSF) could provide etiological clues and diagnostic tools for psychosis; however, an unbiased overview of CSF alterations in individuals with psychotic disorders is lacking. The objective of this study was to summarize all quantifiable findings in CSF from individuals with psychotic disorders compared to healthy controls (HC). Studies published before January 25th, 2023 were identified searching PubMed, EMBASE, Cochrane Library, Web of Science, ClinicalTrials.gov, and PsycINFO. Screening, full-text review, data extraction, and risk of bias assessments were performed by two independent reviewers following PRISMA guidelines. Findings in patients and healthy controls were compared and summarized using random-effects analyses and assessment of publication bias, subgroup and sensitivity analyses were performed. 145 studies, covering 197 biomarkers, were included, of which 163 biomarkers have not previously been investigated in meta-analyses. All studies showed some degree of bias. 55 biomarkers measured in CSF were associated with psychosis and of these were 15 biomarkers measured in ≥2 studies. Patients showed increased levels of noradrenaline (standardized mean difference/SMD, 0.53; 95% confidence interval/CI, 0.16 to 0.90) and its metabolite 3-methoxy-4-hydroxyphenylglycol (SMD, 0.30; 95% CI: 0.05 to 0.55), the serotonin metabolite 5-hydroxyindoleacetic acid (SMD, 0.11; 95% CI: 0.01 to 0.21), the pro-inflammatory neurotransmitter kynurenic acid (SMD, 1.58; 95% CI: 0.34 to 2.81), its precursor kynurenine (SMD,0.99; 95% CI: 0.60 to 1.38), the cytokines interleukin-6 (SMD, 0.58; 95% CI: 0.39 to 0.77) and interleukin-8 (SMD, 0.43; 95% CI: 0.24 to 0.62), the endocannabinoid anandamide (SMD, 0.78; 95% CI: 0.53 to 1.02), albumin ratio (SMD, 0.40; 95% CI: 0.08 to 0.72), total protein (SMD, 0.29; 95% CI: 0.16 to 0.43), immunoglobulin ratio (SMD, 0.45; 95% CI: 0.06 to 0.85) and glucose (SMD, 0.48; 95% CI: 0.01 to 0.94). Neurotensin (SMD, -0.67; 95% CI: -0.89 to -0.46) and γ-aminobutyric acid (SMD, -0.29; 95% CI: -0.50 to -0.09) were decreased. Most biomarkers showed no significant differences, including the dopamine metabolites homovanillic acid and 3,4-dihydroxyphenylacetic acid. These findings suggest that dysregulation of the immune and adrenergic system as well as blood-brain barrier dysfunction are implicated in the pathophysiology of psychotic disorders.
引用
- Rømer TB, Jeppesen R, Christensen RHB, et al. Biomarkers in the cerebrospinal fluid of patients with psychotic disorders compared to healthy controls: a systematic review and meta-analysis. Mol Psychiatry. 2023. PMID: 37169812. doi:10.1038/s41380-023-02059-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。